NEWSpublisher 2007 :: AngloChinese Investments
date from:
date to:
search for string:
» 23/07/2009 [Company watch]
China Aoxing Pharmaceutical Corp. Receives Renewal of GMP Certification for Capsule Dosage Form of Pharmaceutical Products
» 15/03/2010 [Industry news]
Recordati S.p.A And Lee Pharmaceutical Announce Partnership For Zanidip(R) In China
» 26/10/2009 [Finance]
China Growth to Remain Fast in Fourth Quarter, Official Says
» 17/08/2009 [Industry news]
Chindex Posts Profit on Product Sales, Health Services
» 07/05/2010 [Industry news]
Hong Kong: Recall of all products manufactured by Quality Pharmaceutical Lab Ltd
COMPANY NEWS back to previous page show list
»01/03/2010 [Industry news]
Biotech- A Week of activity in the Industry

Industry activities over the past week


China Biotech Week in Review: New Deals in China Life Science by: ChinaBio Today February 28, Three of big pharma’s biggest companies, Merck , Lilly and Pfizer have banded together to create an Asian not-for-profit company that will construct a pharmacogenomic cancer database in Singapore. China\\\'s Ministry of Finance (MoF) announced Friday that the central government had authorized the spending of 37 billion RMB ($5.5 billion) as part of its larger 850 billion RMB healthcare reform, announced last year. WuXi PharmaTech (NYSE: WX) plans to continue its growth by expanding into biotech, safety evaluation and manufacturing. WuXi PharmaTech also reported its Suzhou non-clinical safety testing facility received full accreditation from the Association for the Assessment and Accreditation of Laboratory Animal Care International ((AAALAC). China Cord Blood Corporation (NYSE: CO) has acquired a 20% equity interest in Shandong Cord Blood Bank (SCBB) for $20.5 million Fosun Pharma will invest $9.7 million into Biosino Bio-Technology and Science in a move to increase its presence in the in-vitro diagnostic sector (see story). After the transaction is completed, Fosun will hold approximately 24% of Biosino’s outstanding shares. The shares were priced at HK$2.36 (US$.30), about a 20% discount to Biosino’s recent trading price. Beijing Shenghong Biotechnology Co. has paid 28 million RMB ($4.1 million) to Tibet Rhodiola Pharmaceutical Holding Co. for four new drug projects and research findings. According to an announcement, Tibet Rhodiola and a subsidiary company have spent 24.7 million RMB on the products. Shenghong will also assume debt associated with the drugs, though the amount of debt was not specified. H Lundbeck A/S , a pharmaceutical company headquartered in Denmark, expanded its Asian sales agreement with Teva Pharma to include Azilect (rasagiline), a treatment for Parkinson’s disease . The agreement gives Teva the right to market Azilect in China and five other Asian countries. Lundbeck will be responsible for conducting clinical trials of the drug and obtaining SFDA approval. China Aoxing will collaborate with QRxPharma Limited, a clinical stage Australian pharma, to develop MoxDuo®IV for the China market. MoxDuoIV is an IV formulation of QRxPharma\\\'s patented morphine and oxycodone Dual-Opioid™ technology for the acute treatment of moderate to severe pain. Dishman Chemicals and Pharmaceuticals, the Indian company that offers contract research and manufacturing services, said its new Shanghai manufacturing facility will begin operations almost a year behind schedule. Originally, Dishman expected to have the facility on line in October 2009, but it now expects that all government inspections will be completed in August/September 2010.

AngloChinese Investments ltd.
Home | Company news | TOP 50 | Events | About us
C&F Bright Solutions ltd.